Emcure posts strong Q3FY26 results with ₹2,363 crore & 20.4 % YoY revenue growth

New Delhi: Emcure Pharmaceuticals Ltd. reported a robust performance for the quarter ended December 31, 2025, driven by strong momentum across both domestic and international markets.

Revenue from operations rose 20.4 percent year-on-year to ₹2,363 crore, while EBITDA increased 27.2 percent to ₹460 crore, translating into an EBITDA margin of 19.5 percent. Profit after tax (PAT) stood at ₹231 crore, marking a sharp 48.2 percent year-on-year growth. The quarter’s PAT includes an exceptional expense of ₹38 crore related to labour code changes.

Emcure’s domestic business recorded sales of ₹1,025 crore, up 15.4 percent year-on-year, supported by strong performance across key therapy areas, particularly chronic segments such as cardio and diabetology, along with the impact of new initiatives. During the quarter, the company launched Poviztra®, a biological injectable formulation of semaglutide, in partnership with Novo Nordisk. With this launch of a global innovator product, Emcure aims to establish a strong presence in India’s rapidly evolving weight management segment.

The international business delivered a healthy growth of 24.5 percent, with sales reaching ₹1,338 crore. All geographies reported strong traction. The Rest of the World (RoW) segment grew 30.7 percent, led by robust performance in both ARV and non-ARV portfolios. Europe continued its strong momentum, supported by the rollout of Manx and Amphotericin B, while the Canada business posted a solid growth of 12.8 percent.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said the company delivered a strong quarter, with all businesses outperforming industry growth. He highlighted the launch of Poviztra® as a key milestone that strengthens Emcure’s India portfolio and positions the company advantageously in the fast-growing obesity segment.

Mehta added that the international business continues to scale on the back of differentiated product launches and a robust pipeline. “While we continue to invest in people, products and processes, our focus remains firmly on improving profitability and delivering sustainable growth,” he said.

He further noted that Emcure is consistently expanding its portfolio across focus markets through a combination of in-house R&D and in-licensing, with the Novo Nordisk partnership providing an early-mover advantage in the obesity space.